1. Home
  2. SQNS vs SKYE Comparison

SQNS vs SKYE Comparison

Compare SQNS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SQNS
  • SKYE
  • Stock Information
  • Founded
  • SQNS 2003
  • SKYE 2012
  • Country
  • SQNS France
  • SKYE United States
  • Employees
  • SQNS N/A
  • SKYE N/A
  • Industry
  • SQNS Semiconductors
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • SQNS Technology
  • SKYE Health Care
  • Exchange
  • SQNS Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • SQNS 85.7M
  • SKYE 80.7M
  • IPO Year
  • SQNS 2011
  • SKYE N/A
  • Fundamental
  • Price
  • SQNS $2.97
  • SKYE $3.41
  • Analyst Decision
  • SQNS Strong Buy
  • SKYE Buy
  • Analyst Count
  • SQNS 1
  • SKYE 6
  • Target Price
  • SQNS $7.50
  • SKYE $18.67
  • AVG Volume (30 Days)
  • SQNS 107.6K
  • SKYE 178.5K
  • Earning Date
  • SQNS 02-11-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • SQNS N/A
  • SKYE N/A
  • EPS Growth
  • SQNS N/A
  • SKYE N/A
  • EPS
  • SQNS 1.65
  • SKYE N/A
  • Revenue
  • SQNS $30,555,000.00
  • SKYE N/A
  • Revenue This Year
  • SQNS $10.14
  • SKYE N/A
  • Revenue Next Year
  • SQNS $8.54
  • SKYE N/A
  • P/E Ratio
  • SQNS $1.90
  • SKYE N/A
  • Revenue Growth
  • SQNS N/A
  • SKYE N/A
  • 52 Week Low
  • SQNS $0.85
  • SKYE $2.31
  • 52 Week High
  • SQNS $7.33
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • SQNS 43.35
  • SKYE 52.82
  • Support Level
  • SQNS $3.00
  • SKYE $2.70
  • Resistance Level
  • SQNS $3.39
  • SKYE $3.29
  • Average True Range (ATR)
  • SQNS 0.22
  • SKYE 0.45
  • MACD
  • SQNS -0.03
  • SKYE 0.05
  • Stochastic Oscillator
  • SQNS 0.00
  • SKYE 41.27

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: